Dipraglurant (Extended Release), for the treatment of non-Parkinsonian dystonia.
We are developing an extended release formulation of dipraglurant as a novel orally available NAM for the treatment of dystonia. At the appropriate time we expect to be able to start a Phase 2a proof of concept clinical trial.
There are many types of dystonias that present a significant commercial opportunity for dipraglurant.
We believe that dipraglurant may be a first-in-class oral drug candidate for multiple types of dystonia and offers an innovative and differentiated treatment approach from existing therapies.
We are currently completing preclinical evaluations of dipraglurant in preclinical models of dystonia.